A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome
Latest Information Update: 17 Jun 2022
At a glance
- Drugs Cemdisiran (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 03 Oct 2018 This trial was Completed in Sweden (end date: 2018-09-12), according to European Clinical Trials Database.
- 25 Sep 2018 Status changed from recruiting to discontinued.
- 02 Aug 2018 According to an Alnylam Pharmaceuticals media release, initial data from this trial is expected in 2019.